Two sensitive sandwich-type immunoassays for determination of cellular fibronectin (cFN) in cell culture supernatants and in human plasma were developed. Both assays used a monoclonal antibody with specificity against the EDA sequence, which is characteristic for the cellular form of human and rat FN. Assay 1 involves binding of FN on gelatin-coated microwells followed by reaction with the anti-cFN antibody, whereas in assay 2 the anti-cFN antibody was immobilized first and detection was with an anti-FN antiserum. Time-resolved fluorescence spectrophotometry with measurement of an Eu3 chelator after dissociation of the solid-phase complexes with urea/sodium dodecyl sulfate in the presence of excess Eu3 was the detection method. The detection limit of the new assays was between 2.6 and 4.0 g/L cFN. In serial dilution of human plasma samples, parallelism with the calibration curve was obtained over the whole measuring range (12-1000 g/L) with assay 2, whereas assay 1 had deviations of the dilution curves at concentrations 100 g/L. The between-run CVs for assays 1 and 2 were 11.4% and 7.2%, respectively, at a concentration of 200 g/L (median value of 18 experiments). Respective within-series CVs of 4.3% and 4.7% were obtained at the same concentration. The recovery of added cFN from human plasma was between 90% and 96%. FN (tFN) concentration, i.e., the Abt.
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Two sensitive sandwich-type immunoassays for determination of cellular fibronectin (cFN) in cell culture supernatants and in human plasma were developed. Both assays used a monoclonal antibody with specificity against the EDA sequence, which is characteristic for the cellular form of human and rat FN. Assay 1 involves binding of FN on gelatin-coated microwells followed by reaction with the anti-cFN antibody, whereas in assay 2 the anti-cFN antibody was immobilized first and detection was with an anti-FN antiserum. Time-resolved fluorescence spectrophotometry with measurement of an Eu3 chelator after dissociation of the solid-phase complexes with urea/sodium dodecyl sulfate in the presence of excess Eu3 was the detection method. The detection limit of the new assays was between 2.6 and 4.0 g/L cFN. In serial dilution of human plasma samples, parallelism with the calibration curve was obtained over the whole measuring range (12-1000 g/L) with assay 2, whereas assay 1 had deviations of the dilution curves at concentrations 100 g/L. The between-run CVs for assays 1 and 2 were 11.4% and 7.2%, respectively, at a concentration of 200 g/L (median value of 18 experiments). Respective within-series CVs of 4.3% and 4.7% were obtained at the same concentration. The recovery of added cFN from human plasma was between 90% and 96%. antibody. This antibody is directed against the EDA sequence, which is specific for the cellular form of human and rat FN. Assay 1 is based on the binding of FN on solid-phase coated gelatin followed by the specific detection of cFN with the DH1 antibody. In assay 2 the DH1 antibody is used first and a polyvalent anti-FN antiserum is used in the second step. The biotin/streptavidin (SA) system, using SA labeled with BCPDA, is used for convenient detection.
Materials and Methods
Materials
Synthesis
of BCPDA was performed as described (12) . SA was labeled with BCPDA and separated from remaining BCPDA as described previously (11) . Rat cFN and human pFN were purified from culture supernates of rat fibroblasts grown in FN-free medium and from human plasma, respectively, by gelatin aflinity chromatography on Gelatin-Sepharose 4B (Pharmacia, Uppsala, Sweden), according to Ruoslahti et al. (13) 
Assay Procedures
To coat the microwells, we used a solution of 0.05 mol/L NaHCO3, pH 9.1. The washing solution contained 9 g/L NaCl, 0.5 g/L Tween 20, and 0.5 g/L NaN3. The assay buffer was prepared by dissolving 5 g of bovine serum albumin, 0.05 g of NaN3, and 0.05 mol of Tris in 1 L of H20, and adjusting the pH to 7.7.
The volume used for calibrators, samples, antibodies, and SA-BCPDA was 100 giL/well, whereas the urea! SDSfEu3 solution was used at 250 diwell.
Assay 1. Microtiter strips (flat-bottom, 12 x 1 wells, MaxiSorp Immuno modules;
Nunc, Wiesbaden-Biebrich, Germany) were coated overnight at 4#{176}C with 10 mg/L gelatin in coating solution. After washing, the wells were filled for blocking with assay buffer and stored at 4 #{176}C until assay. Calibrators and samples were diluted in an assay buffer and incubated for 1 h. Anti-cFN antibody was added at 100 g/L for 1 h followed by 30-mm incubations with biotinylated anti-mouse theoretical value. In fetal calf serum, diluted 1:5 in assay buffer, the recovery of different amounts of added cFN was between 90% and 105%. Because of the nonparallelism observed with plasma samples, recovery studies were not performed with assay 1. 
Human Plasma Samples
